arrow
L

Luca Galli

irccs istituto oncologico veneto (iov)
H指数:34
被引数:4,339

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)

Avelumab维持治疗在晚期尿路上皮癌中的真实世界有效性:来自意大利多中心MALVA研究(Meet-URO 25)的结果

2025-12-010
PRE
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感型前列腺癌最佳治疗方法: 系统评价和网络荟萃分析

2025-11-170
OA
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

肾细胞癌辅助性帕博利珠单抗的实证据:多中心真实世界ARON-1研究的结果

2025-11-140
OAAI
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study

关于肌肉浸润性膀胱癌围手术期化疗的疗效和利用率的意大利临床实践快照: realsitle研究

IN VIVO
IF1.8
2025-11-010
PRE
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)

卡博替尼在转移性肾细胞癌一线治疗中的真实世界应用:CabFRONT研究(Meet-URO 24)

2025-10-130
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

纳武利尤单抗联合卡博替尼治疗转移性肾细胞癌:国际ARON-1研究的真实世界证据

2025-07-270
OA
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

mRCC骨转移患者的钠水平和免疫治疗功效: Meet-Uro 15研究的子分析

2024-07-055
OAAI
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

接受免疫治疗的晚期肾细胞癌患者的肿瘤微环境分析 (Meet-URO 18研究)

2024-06-120
PRE
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

Pembrolizumab在晚期上尿路尿路上皮癌患者中的应用: 来自ARON-2项目的真实世界研究

2024-06-083
PRE
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

EV-301既往接受过治疗的晚期尿路上皮癌患者的健康相关生活质量: Enfortumab Vedotin与化疗的3期试验

2024-06-014
OAAI
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

局部/局部晚期疾病的初始管理方法对于指导转移性去势抵抗性前列腺癌的治疗至关重要

2024-02-121
PRE
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

接受nivolumab治疗的转移性肾细胞癌患者的策略失败和治疗超过进展的时间: 对Meet-URO 15研究的事后分析

2024-02-121
OAAI
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

免疫肿瘤学联合治疗的晚期肾细胞癌和中度或低风险国际转移性肾细胞癌数据库联盟标准患者的真实世界结果: 风险组的差异有效性?

2024-02-0118
PRE
Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)

接受nivolumab治疗的转移性肾细胞癌 (mRCC) 患者 (pts) 的治疗失败时间 (TTF) 和治疗超过进展 (TBP): 生存结果和临床获益的治疗策略 (meet-uro 15)

2023-10-011
OA